Investors

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Aldeyra Therapeutics Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Phase 2b Results for Topical Ocular Reproxalap in Dry Eye Disease Expected in Late Third Quarter or Early Fourth Quarter 2018 Clinical Results from Investigator-Sponsored Trial of ADX-1612 in Mesothelioma Expected to be Released at the International Association for the Study of Lung Cancer
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2018 Financial Results and Corporate Update
LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, will hold a conference call on Thursday, August 9, 2018 ,
View HTML
Toggle Summary Aldeyra Therapeutics to Present at the 38th Annual Canaccord Genuity Growth Conference
LEXINGTON, Mass. , Aug. 1, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C.
View HTML
Toggle Summary Aldeyra Therapeutics Appoints Joshua Reed as Chief Financial Officer
LEXINGTON, Mass. , July 31, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced the appointment of Joshua Reed as Chief
View HTML
Toggle Summary Aldeyra Therapeutics Announces First Patient Enrolled in Sjögren-Larsson Syndrome Pivotal Phase 3 Clinical Trial
LEXINGTON, Mass. , July 24, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the first patient has enrolled in a
View HTML
Toggle Summary Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2b Clinical Trial
LEXINGTON, Mass. , July 12, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to the development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced that the last patient has completed dosing
View HTML
Toggle Summary Aldeyra Therapeutics Announces Development Programs at 2018 Research Day
Expanded Pipeline Features Distinct Mechanisms of Action Across Five Product Candidates Three Additional Clinical Programs Planned for 2019 LEXINGTON, Mass. , June 26, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to the development of
View HTML
Toggle Summary Aldeyra Therapeutics Joins the Russell 3000® and 2000® Indexes
LEXINGTON, Mass. , June 25, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the Company was added to the
View HTML
Toggle Summary Aldeyra Therapeutics Announces 2018 Research Day
LEXINGTON, Mass. , June 20, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a Research Day to
View HTML
Toggle Summary Aldeyra Therapeutics Announces First Quarter 2018 Financial Results
LEXINGTON, Mass. , May 15, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc.  (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results for the first quarter
View HTML